1887

Abstract

Restricted replication in the respiratory tract of rhesus monkeys is an intrinsic property of bovine parainfluenza virus type 3 (bPIV-3) strains. This host range phenotype of bPIV-3 has been utilized as a marker to evaluate the attenuation of bPIV-3 vaccines for human use. Two safety, immunogenicity and efficacy studies in primates evaluated and compared three human parainfluenza virus type 3 (hPIV-3) vaccine candidates: biologically derived bPIV-3, a plasmid-derived bPIV-3 (r-bPIV-3) and a chimeric bovine/human PIV-3 (b/hPIV-3). These studies also examined the feasibility of substituting Vero cells, cultured in the presence or absence of foetal bovine serum, for foetal rhesus lung-2 (FRhL-2) cells as the tissue culture substrate for the production of bPIV-3 vaccine. The results demonstrated that (i) Vero cell-produced bPIV-3 was as attenuated, immunogenic and efficacious as bPIV-3 vaccine grown in FRhL-2 cells, (ii) plasmid-derived bPIV-3 was as attenuated, immunogenic and efficacious as the biologically derived bPIV-3 and (iii) the b/hPIV-3 chimera displayed an intermediate attenuation phenotype and protected animals completely from hPIV-3 challenge. These results support the use of bPIV-3 vaccines propagated in Vero cells in human clinical trials and the use of b/hPIV-3 as a virus vaccine vector to express foreign viral antigens.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19522-0
2003-12-01
2020-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/12/vir843253.html?itemId=/content/journal/jgv/10.1099/vir.0.19522-0&mimeType=html&fmt=ahah

References

  1. Bailley J. E., McAuliffe J. M., Skiadopoulos M. H., Collins P. L., Murphy B. R. 2000; Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates. Virus Genes 20:173–182
    [Google Scholar]
  2. Coelingh K. J., Winter C. C., Murphy B. R., Rice J. M., Kimball P. C., Olmsted R. A., Collins P. L. 1986; Conserved epitopes on the hemagglutinin–neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 60:90–96
    [Google Scholar]
  3. Greenberg D. P., Yeh S., Yogev R. 7 other authors 1999; Evaluation of the safety, immunogenicity, and virus shedding of an intranasal live attenuated bovine parainfluenza virus type 3 vaccine in infants. Annual Meeting of the Pediatric Academic Societies (San Francisco, USA: 1–4 May 1999 Abstract #942
    [Google Scholar]
  4. Haller A. A., Miller T., Mitiku M., Coelingh K. L. 2000; Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 74:11626–11635
    [Google Scholar]
  5. Haller A. A., MacPhail M., Mitiku M., Tang R. S. 2001; A single amino acid substitution in the viral polymerase creates a temperature-sensitive and attenuated recombinant bovine parainfluenza virus type 3. Virology 288:342–350
    [Google Scholar]
  6. Hsuing G. D. 1982 Diagnostic Virology , 3rd edn.p– 143 Princeton, NJ: Yale University Press;
    [Google Scholar]
  7. Karron R. A., Wright P. F., Hall S. L. 7 other authors 1995; A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 171:1107–1114
    [Google Scholar]
  8. Karron R. A., Makhene M., Gay K., Wilson M. H., Clements M. L., Murphy B. R. 1996; Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 15:650–654
    [Google Scholar]
  9. Klippmark E., Rydbeck R., Shibuta H., Norrby E. 1990; Antigenic variation of human and bovine parainfluenza virus type 3 strains. J Gen Virol 71:1577–1580
    [Google Scholar]
  10. Lee M. S., Greenberg D. P., Yeh S. H. 12 other authors 2001; Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. J Infect Dis 184:909–913
    [Google Scholar]
  11. Reed L. J., Muench H. 1938; A simple method for estimating fifty percent end points. Am J Hyg 27:493–497
    [Google Scholar]
  12. Schmidt A. C., McAuliffe J. M., Huang A., Surman S. R., Bailly J. E., Elkins W. R., Collins P. L., Murphy B. R., Skiadopoulos M. H. 2000; Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin–neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74:8922–8929
    [Google Scholar]
  13. van Wyke Coelingh K. L., Winter C. C., Tierney E. L., London W. T., Murphy B. R. 1988; Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J Infect Dis 157:655–662
    [Google Scholar]
  14. Welliver R. C., Wong D. T., Sun M., McCarthy N. 1986; Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis. Am J Dis Child 140:34–40
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19522-0
Loading
/content/journal/jgv/10.1099/vir.0.19522-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error